Neuroinnovatech Parkinson's Non-Motor Symptoms Therapeutic Agent, Apr 23, 2026
Summary
NEUROINNOVATECH ApS has filed USPTO patent application US20260108494A1 for a therapeutic agent targeting serotonergic or dopaminergic system-related diseases, specifically the mental dysfunction and non-motor symptoms of Parkinson's disease. The application includes a treatment and recurrence-prevention method using a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Application No. 19423150 was filed on 2025-12-17 with inventors Taro Kato and Satoko Shimizu.
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 211 changes logged to date.
What changed
NEUROINNOVATECH ApS filed USPTO patent application US20260108494A1 for a therapeutic agent and treatment method targeting serotonergic or dopaminergic system-related diseases, specifically the non-motor and mental dysfunction symptoms of Parkinson's disease. The application claims a compound represented by formula (1) or a pharmaceutically acceptable salt as exhibiting both therapeutic and recurrence-prevention effects for the specified conditions.
For pharmaceutical and biotech companies operating in CNS therapeutics or movement disorders, this application signals active IP protection around novel serotonergic/dopaminergic approaches for Parkinson's non-motor symptoms. Parties pursuing similar CNS therapeutic development should review Freedom to Operate positions relative to the claimed compound class and consider monitoring this application's prosecution for potential licensing or citation purposes.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE
Application US20260108494A1 Kind: A1 Apr 23, 2026
Assignee
NEUROINNOVATECH ApS
Inventors
Taro KATO, Satoko SHIMIZU
Abstract
The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same.
CPC Classifications
A61K 31/415 A61K 45/06 A61P 25/08 A61P 25/22 A61P 25/24
Filing Date
2025-12-17
Application No.
19423150
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.